IPO Boutique

Karyopharm Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Karyopharm Therapeutics, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Karyopharm TherapeuticsKPTI -
NASDAQ
$14.00-$16.00 $16.00 $17.865.7 million11/6/2013
BofA Merrill Lynch, J.P. Morgan, Leerink Partners
Co-Manager(s):
JMP Securities, Oppenheimer & Co.
Health Care
Filing(s):

Filed 2013-10-04
Terms Added 2013-10-13



Karyopharm Therapeutics Quote & Chart - Click for current quote - KPTI

About Karyopharm Therapeutics (adapted from Karyopharm Therapeutics prospectus):
They are a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "KPTI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved